Clinical trials: Cardiovascular Risk Factor
Cerebral Stroke, Thrombosis, Deep Vein
A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery
To characterize and analyze the number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with Apixaban, according to therapeutic indications approved in Mexico.
- Conditions
- Cerebral Stroke, Thrombosis, Deep Vein, Pulmonary Embolism
- Trial name
- NCT03804125
- Sponsor
- Pfizer
Primary Hypercholesterolemia
A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy With a Statin in Participants With Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors (P02173)
This is a study to evaluate the lipid-altering efficacy, safety, and tolerability of ezetimibe when added to ongoing therapy with an 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin) in participants…
- Trial name
- NCT03882905
- Testing
- Ezetimibe, Simivastatin, Statin
- Volunteers
- 769 people
- Sponsor
- Organon and Co
Type 2 Diabetes, Cardiovascular Disease
Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease
The purpose of this study is to demonstrate no excess risk of cardiovascular (CV) composite events exists following long term treatment with TAK-875 compared with placebo.
- Trial name
- NCT01609582
- Testing
- TAK-875
- Where
- 584 sites in United States, Argentina and 30 more
- Volunteers
- 3,207 people
- Sponsor
- Takeda
Nutritional and Metabolic Diseases, Inflammation
A Study of Strawberries and Disease Risk
The purpose of this study is to test whether compounds found in strawberries (polyphenolics which are typically found in berry products, tea, coffee, red wine, and chocolate) will help reduce insulin resistance and inflammation…
- Conditions
- Nutritional and Metabolic Diseases, Inflammation, Physiological Responses
- Trial name
- STRB (NCT01199848)
- Testing
- 10G, 20G, 40G
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Rheumatoid Arthritis
A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors
This randomized, open-label, parallel-group, multicenter study will evaluate the rate of cardiovascular events with tocilizumab in comparison to etanercept in participants with rheumatoid arthritis (RA).
- Trial name
- NCT01331837
- Testing
- Etanercept, Tocilizumab
- Where
- 428 sites in United States, Argentina and 29 more
- Volunteers
- 3,080 people
- Sponsor
- Hoffmann-La Roche
Obesity, Microalbuminuria
Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk Factors
Primary objective: To assess the effect on microalbuminuria levels of treatment with rimonabant 20 mg versus a placebo during a 12 month period.
- Conditions
- Obesity, Microalbuminuria, Diabetes Mellitus, Type 2, Dyslipidemia
- Trial name
- RIALTO (NCT00458081)
- Testing
- Rimonabant
- Where
- Spain
- Volunteers
- 174 people
- Sponsor
- Sanofi
Cardiovascular Diseases
The Effect of Theobromine on Blood Lipid Parameters in Healthy Subjects
The purpose of this study is to determine the effect of theobromine on blood lipid parameters in healthy subjects. Secondary objectives are to determine the effect of cocoa and an interaction effect of cocoa and theobromine on…
- Trial name
- NCT01481389
- Testing
- Theobromine, Cocoa, Cocoa and theobromine
- Where
- France
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Unilever R&D
Peripheral Arterial Disease
Audit and Screening Study to Determine the Prevalence of Peripheral Arterial Disease
The primary objective of the study is to establish the prevalence of lower extremity peripheral arterial disease (PAD), defined as an ankle-brachial index of less than or equal to 0.9, in subjects with at least two of the…
- Trial name
- ACHILLES (NCT00928629)
- Testing
- Ankle-brachial index (ABI) Screening Test
- Where
- 23 sites in Australia
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Coronary Disease
RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome
The purpose of this trial is to evaluate the safety and indicators of efficacy of up to 4 doses of orally administered dabigatran etexilate, administered twice daily, compared to placebo when given in addition to dual…
- Trial name
- NCT00621855
- Testing
- dabigatran etexilate
- Where
- 167 sites in United States, Belgium and 22 more
- Volunteers
- 1,878 people
- Sponsor
- Boehringer Ingelheim
Cardiovascular Disease
Study of Artery Conditions of 'At-risk' Asian People Not on Lipid-lowering Drugs
The purpose of this study is to obtain the distribution of measurements of the intima media thickness of carotid arteries in people with high cardiovascular risk.
- Trial name
- CIMT (NCT00970918)
- Testing
- Measurement of the Carotid Intima Media thickness, Blood sample testing for hs-CRP
- Where
- 19 sites in China, India and 7 more
- Volunteers
- 2,609 people
- Sponsor
- AstraZeneca
Heart Failure, Type 2 Diabetes Mellitus
Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
The primary objective of the study was to compare the effect of sotagliflozin to placebo on total occurrences of cardiovascular (CV) death, hospitalization for heart failure [HHF], and urgent visit for heart failure [HF] in…
- Conditions
- Heart Failure, Type 2 Diabetes Mellitus, Chronic Kidney Diseases
- Trial name
- SCORED (NCT03315143)
- Testing
- Sotagliflozin
- Where
- 754 sites in United States, Argentina and 43 more
- Volunteers
- 10,584 people
- Sponsor
- Lexicon Pharmaceuticals
Diabetes Mellitus, Type 2
A Study of People With Type 2 Diabetes Who Have Diseases That Affect the Heart and Blood Vessels. The Study Will Also Look at the Treatment of a Group of These People in Hospitals in Portugal
This study aims to estimate the number of patients with cardiovascular disease and risk factors in patients who had been diagnosed with type 2 diabetes mellitus.
- Trial name
- PICT2RE (NCT03797885)
- Testing
- No treatment given
- Where
- 14 sites in Portugal
- Volunteers
- 730 people
- Sponsor
- Novo Nordisk A/S
Traumatic Subdural Hematoma
Factors Influencing Readmission Rates of Acute Traumatic Subdural Hematoma in the Elderly
Acute traumatic subdural hematomas (TSDH) readmission rate is high (27.8%) with an increase in morbidity and cost for the elderly.
- Trial name
- NCT03878043
- Testing
- Follow-up Care
- Where
- United States
- Volunteers
- 167 people, healthy volunteers welcome
- Sponsor
- Tarik Wasfie, MD
Cardiovascular Disease, High Cardiovascular Risk
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with cardiovascular (CV) disease and/or multiple CV risk factors.
- Conditions
- Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight
- Trial name
- CAMELLIA-TIMI (NCT02019264)
- Testing
- Lorcaserin hydrochloride
- Where
- 499 sites in United States, Australia and 6 more
- Volunteers
- 14,673 people
- Sponsor
- Eisai Inc.
Obesity
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
This study is open to adults who are at least 18 years old and have a body mass index (BMI) of 27 kg/m2 or more. People can take part if they have cardiovascular or chronic kidney disease.
- Trial name
- NCT06077864
- Testing
- survodutide
- Where
- 540 sites in United States, Argentina and 33 more
- Volunteers
- 5,531 people
- Sponsor
- Boehringer Ingelheim
Cardiac Transplant Failure, Cardiac Transplant Rejection
Outcomes AlloMap Registry: the Long-term Management and Outcomes of Heart Transplant Recipients With AlloMap Testing
The objective of this registry is to observe short and long term clinical outcomes in heart transplant recipients who receive regular AlloMap testing as part of allograft rejection surveillance.
- Conditions
- Cardiac Transplant Failure, Cardiac Transplant Rejection, Heart Diseases
- Trial name
- OAR (NCT01833195)
- Where
- 36 sites in United States
- Volunteers
- 2,444 people, healthy volunteers welcome
- Sponsor
- CareDx
Obesity, Overweight
Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects
The purpose of this Phase 3b study is to assess the effects of combination therapy with naltrexone SR/bupropion SR (NB) used in conjunction with a comprehensive lifestyle intervention (CLI) and in a manner consistent with its…
- Trial name
- NCT01764386
- Testing
- NB, CLI, Usual Care
- Where
- 15 sites in United States
- Volunteers
- 242 people
- Sponsor
- Orexigen Therapeutics, Inc
Hyperlipidemia
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events
This study is a multicenter, randomized study in subjects with high cholesterol receiving highly effective statins to assess the efficacy, safety and tolerability of Bococizumab (PF-04950615;RN316) to lower LDL-C.
- Trial name
- SPIRE-LDL (NCT01968967)
- Testing
- Bococizumab (PF-04950615; RN316)
- Where
- 249 sites in United States, Canada and 10 more
- Volunteers
- 2,139 people
- Sponsor
- Pfizer
Cardiovascular Risk Factors, Cardiovascular Diseases
Management of Cardiovascular Risk Factors
This practical experience should report a retrospective collection of data regarding cardiovascular risk factors of cardiovascular diseases.
- Trial name
- NCT00848380
- Where
- 36 sites in Switzerland
- Volunteers
- 1,492 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hypogonadism
Association Between the Prevalence of Cardiovascular Risk Factors and New Use of Testosterone
We will investigate if testosterone is preferentially given to patients at higher risk of cardiovascular events. If this is the case, then observational studies may be prone to selection bias resulting in overestimation of the…
- Trial name
- NCT03484260
- Testing
- Testosterone Product
- Where
- Germany
- Volunteers
- 27,778 people
- Sponsor
- Bayer